TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36161968

Group type: COMPARATOR
Intervention: Standard condition (standard elicitation of barriers)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Impossible condition (elicitation using alternative words)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Incentive condition (motivation held constant by the use of a hypothetical incentive)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Vignette condition (participants were primed with a vignette)
Number of subjects: 253
Study: 33346093

Group type: EXPERIMENTAL
Intervention: Dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) blood volume (BV) changes
Number of subjects: 32
Study: 34883036

Group type: EXPERIMENTAL
Intervention: LymphAssist IPC regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sequential IPC regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (LymphAssist and Sequential IPC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IPC (both regimens)
Number of subjects: 40
Study: 34863622

Group type: EXPERIMENTAL
Intervention: Caudal epidural block (CEB) with GA, 0.2% ropivacaine 1 ml/kg (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia without CEB (n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caudal epidural block (CEB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia without CEB
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative fentanyl consumption
Number of subjects: 50
Study: 32074419

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention involving home visits by trained community health workers for blood-pressure monitoring and counseling, training of physicians, and care coordination in the public sector.
Number of subjects: 2645

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 2645

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention.
Number of subjects: 2645
Study: 35777410

Group type: EXPERIMENTAL
Intervention: 6-month PrEP dispensing plus interim blood-based HIVST (with biannual clinic visits)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: 6-month PrEP dispensing plus interim oral fluid-based HIVST (with biannual clinic visits)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Standard of care (3-month PrEP dispensing with quarterly clinic visits)
Number of subjects: 495
Study: 33979838

Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy overweight or obese status
Number of subjects: 405

Group type: COMPARATOR
Intervention: Maternal iron status
Number of subjects: 405

Group type: COMPARATOR
Intervention: Neonatal iron status
Number of subjects: 405
Study: 36164947

Group type: EXPERIMENTAL
Intervention: Omalizumab (300 mg/month, min-max=150-1200 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg/month for 2 patients with EGPA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Mepolizumab
Number of subjects: 202

Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Biological treatment interruption
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Duration of biological use
Number of subjects: 202
Study: 34051124

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 34779658

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 33822368

Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with lenalidomide and dexamethasone (D‐Rd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study: 32901243

Group type: EXPERIMENTAL
Intervention: Desensitizing‐containing hydrogen peroxide (5% potassium nitrate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desensitizing‐free hydrogen peroxide (35%)
Number of subjects: 60
Study: 33751636

Group type: COMPARATOR
Intervention: SNP-testing procedure for binary clinical outcomes
Number of subjects: 0
Study: 34230150

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with TIP (cisplatin, ifosfamide, paclitaxel)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with TIP (cisplatin, ifosfamide, paclitaxel) followed by total mesometrial resection (TMMR) and adjuvant chemotherapy (ACT)
Number of subjects: 12
Study: 35604179

Group type: EXPERIMENTAL
Intervention: Self-made acne prescription taken orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chinese patent medicine Qingre Anchuang taken orally (Control)
Number of subjects: 20
Study: 33694196

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 32109379

Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 35770629

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 34364382

Group type: EXPERIMENTAL
Intervention: Nomograms for overall survival (OS) and cancer-specific survival (CSS) based on independent prognostic factors including age, sex, tumor size, grade, chemotherapy, N stage, and M stage.
Number of subjects: 1196
Study: 35739339

Group type: EXPERIMENTAL
Intervention: Partial KiVa group (did not include the online game)
Number of subjects: 5923

Group type: EXPERIMENTAL
Intervention: Full KiVa group (including the online game)
Number of subjects: 5923

Group type: COMPARATOR
Intervention: Control group (regular school curriculum)
Number of subjects: 5923
Study: 33277281

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (FGM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose
Number of subjects: 104
Study: 35124807

Group type: EXPERIMENTAL
Intervention: Sleep hygiene training (two sessions a week for 2 weeks)
Number of subjects: 134
Study: 34584281

Group type: EXPERIMENTAL
Intervention: Baska Mask
Number of subjects: 84

Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 84
Study: 35508084

Group type: EXPERIMENTAL
Intervention: Educational intervention based on positive references
Number of subjects: 40
Study: 32450869

Group type: EXPERIMENTAL
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 4983
Study: 36617990

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 269

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 269
Study: 33643416

Group type: EXPERIMENTAL
Intervention: Diagnostic score report (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall percentage grade of performance (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 32681930

Group type: EXPERIMENTAL
Intervention: Radiomic index based on Center of Mass Shift (COMshift) and 10th Intensity percentile (P10)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Radiomic index stratification by quartile values
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Radiomic index validation cohort
Number of subjects: 176
Study: 36143879

Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion (TCI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane inhalation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 33152443

Group type: EXPERIMENTAL
Intervention: Clinical instrumental improvisation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Clinical vocal improvisation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vocal intervention
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Music therapy (MT)
Number of subjects: 87
Study: 33514841

Group type: EXPERIMENTAL
Intervention: Forecasted economic anxiety
Number of subjects: 97

Group type: COMPARATOR
Intervention: No-anxiety control condition
Number of subjects: 97
Study: 33028319

Group type: EXPERIMENTAL
Intervention: REACH Pregnancy Circles intervention
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1732
Study: 35476124

Group type: EXPERIMENTAL
Intervention: Electronic tool to detect and reduce complexity of drug treatment
Number of subjects: 139
Study: 33206382

Group type: EXPERIMENTAL
Intervention: 8U/kg abobotulinumtoxinA injections
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 16U/kg abobotulinumtoxinA injections
Number of subjects: 210

Group type: COMPARATOR
Intervention: All groups (including control 2U/kg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 8U/kg or 16U/kg abobotulinumtoxinA plus HETP
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (2U/kg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 8U/kg group
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 16U/kg group
Number of subjects: 210
Study: 35064866

Group type: EXPERIMENTAL
Intervention: Aspiration
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham Aspiration
Number of subjects: 14
Study: 33481875

Group type: EXPERIMENTAL
Intervention: French AmbUlatory Cesarean Section (FAUCS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Misgav Ladach cesarean section (MLCS)
Number of subjects: 100
Study: 33023849

Group type: EXPERIMENTAL
Intervention: Anterior osteotomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-osteotomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (infants with normal pelvic anatomy)
Number of subjects: 20
Study: 35688588

Group type: EXPERIMENTAL
Intervention: Nurse-led peer support intervention (6 weekly peer support sessions facilitated by a nurse and at least one peer facilitator)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (weekly individual face-to-face sessions for 6 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nurse-led peer support intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 33080005

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg up to 800 mg, intravenous within 8 hours from randomization, followed by a second dose after 12 hours)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard care (supportive care following clinical center protocols)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 126
Study: 32847020

Group type: EXPERIMENTAL
Intervention: Home-based active games intervention with strengthening and jumping exercises for 24 weeks
Number of subjects: 111
Study: 35213716

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Histamine-2 receptor blockers
Number of subjects: 1628
Study: 33974131

Group type: EXPERIMENTAL
Intervention: Telemedicine appointment by a physician
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Telemedicine appointment by a medical assistant (RFA)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Telemedicine consultation (both physician and RFA)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Vaccination behavior
Number of subjects: 112
Study: 34334087

Group type: EXPERIMENTAL
Intervention: Sensorimotor training (8 weeks, 3 days/week) + diabetes and foot care education
Number of subjects: 37

Group type: COMPARATOR
Intervention: Diabetes and foot care education only
Number of subjects: 37
Study: 32086355

Group type: EXPERIMENTAL
Intervention: Intervention group (Wikipedia pages seeded with tables of best evidence and hyperlinks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (Wikipedia pages left unchanged)
Number of subjects: 70
Study: 32185993

Group type: EXPERIMENTAL
Intervention: Pricking and penetrating moxibustion therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Penetrating moxibustion therapy (Control)
Number of subjects: 60
Study: 35202842

Group type: EXPERIMENTAL
Intervention: Educational tools to engage local communities, building partnerships within local PD communities, and recruiting stakeholders to reimagine medical and research information for the community.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (specifics not provided).
Number of subjects: 0
Study: 36223435

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 33841399

Group type: EXPERIMENTAL
Intervention: Probiotic cocktail
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 32078683

Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg tenecteplase (maximum, 40 mg; n = 150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: 0.25 mg/kg tenecteplase (maximum, 25 mg; n = 150)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg tenecteplase
Number of subjects: 300

Group type: COMPARATOR
Intervention: 0.25 mg/kg tenecteplase
Number of subjects: 300
Study: 33526633

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 4540
Study: 33208207

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no recombinant factor VIIa)
Number of subjects: 57
Study: 32379763

Group type: EXPERIMENTAL
Intervention: ramucirumab (RAM) plus paclitaxel (PAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo (PLA) plus paclitaxel (PAC)
Number of subjects: 0
Study: 35493500

Group type: EXPERIMENTAL
Intervention: Rituximab (maintenance therapy)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Remdesivir, hyperimmune plasma, and corticosteroids (treatment during flares)
Number of subjects: 2
Study: 33484269

Group type: EXPERIMENTAL
Intervention: Video intervention (90-second video featuring a young woman with schizophrenia)
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Written vignette (description of the same content)
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Nonintervention control arm
Number of subjects: 1203
Study: 33138171

Group type: EXPERIMENTAL
Intervention: Task Specific Training (TST) for the affected UL, one hour, three sessions per week for six weeks.
Number of subjects: 40
Study: 35216037

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFN-β)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 32788067

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment for Bell's palsy
Number of subjects: 644

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644
Study: 35218604

Group type: EXPERIMENTAL
Intervention: Trazpiroben 25 mg alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Trazpiroben 25 mg with esomeprazole 40 mg
Number of subjects: 12
Study: 33439131

Group type: EXPERIMENTAL
Intervention: High modality interactivity and high message interactivity
Number of subjects: 293

Group type: COMPARATOR
Intervention: Low message interactivity
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: High modality interactivity
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: High message interactivity
Number of subjects: 293
Study: 32223086

Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg) plus tamsulosin hydrochloride (0.2 mg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg) only
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 32620020

Group type: EXPERIMENTAL
Intervention: Bolus nasogastric tube feeding
Number of subjects: 98

Group type: COMPARATOR
Intervention: Bolus orogastric tube feeding
Number of subjects: 98
Study: 32086898

Group type: EXPERIMENTAL
Intervention: Spirolactone 20 mg orally twice a day for 7 days after H-UPPP
Number of subjects: 50
Study: 35220140

Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg (LEM5)
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study: 34259423

Group type: EXPERIMENTAL
Intervention: ERAS group (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: non-ERAS group D (BMI ≥ 28 kg/m2, n = 22)
Number of subjects: 80
Study: 32345377

Group type: EXPERIMENTAL
Intervention: Conservative surgery combined with triptorelin acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative surgery only
Number of subjects: 0
Study: 36299392

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (HIIT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study: 35304048

Group type: EXPERIMENTAL
Intervention: Fish oil + placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Probiotics + placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Fish oil + probiotics
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 438
Study: 33935058

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: HVPS
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 35551112

Group type: EXPERIMENTAL
Intervention: i-BFR30 (low intensity with intermittent BFR, ∼150 mm Hg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: c-BFR30 (low intensity with continuous BFR, ∼100 mm Hg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HI (high intensity with unrestricted blood flow)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All BFR conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON30 (control, low intensity with unrestricted blood flow)
Number of subjects: 12
Study: 34086101

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 2779

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2779

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2779
Study: 32548624

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control
Number of subjects: 233
Study: 34282866

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment every 2 months for a total of 3 sessions
Number of subjects: 23
Study: 32811402

Group type: EXPERIMENTAL
Intervention: Insall-Salvati Index (ISI) measurement
Number of subjects: 45
Study: 33004277

Group type: EXPERIMENTAL
Intervention: Anti-D immunoglobulin (RhIg) prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVIg treatment
Number of subjects: 0
Study: 34526250

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (study group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (without RA)
Number of subjects: 100
Study: 32020731

Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: acarbose
Number of subjects: 481
Study: 35181553

Group type: EXPERIMENTAL
Intervention: Centralized call center for death event identification
Number of subjects: 2284

Group type: COMPARATOR
Intervention: National Death Index (NDI)
Number of subjects: 2284

Group type: EXPERIMENTAL
Intervention: Centralized call center
Number of subjects: 2284

Group type: EXPERIMENTAL
Intervention: Cohen's kappa coefficient
Number of subjects: 2284
Study: 33960540

Group type: EXPERIMENTAL
Intervention: Leukoreduced (LR) packed red blood cells (PRBC)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Nonleukoreduced (N-LR) packed red blood cells (PRBC)
Number of subjects: 194
Study: 33096736

Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hospital monitoring
Number of subjects: 49
Study: 36250647

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for families of youth with type 1 diabetes over 2 years
Number of subjects: 390
Study: 33241960

Group type: EXPERIMENTAL
Intervention: BAT2506
Number of subjects: 180

Group type: COMPARATOR
Intervention: golimumab
Number of subjects: 180
Study: 35087707

Group type: EXPERIMENTAL
Intervention: Institution based cardiac rehabilitation (IBCR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Home based cardiac rehabilitation (HBCR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (Observational arm)
Number of subjects: 100
Study: 33590901

Group type: EXPERIMENTAL
Intervention: Combination of nitazoxanide, ribavirin, and ivermectin plus Zinc supplement
Number of subjects: 113

Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 113
Study: 35403398

Group type: EXPERIMENTAL
Intervention: CO2 laser moxibustion
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham laser moxibustion
Number of subjects: 76
Study: 34264861

Group type: EXPERIMENTAL
Intervention: Hicaz maqam music for 30 minutes a day for a week
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Huseyni maqam music for 30 minutes a day for a week
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study: 33300290

Group type: EXPERIMENTAL
Intervention: DASH-high sodium (n = 199)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: DASH-low sodium (n = 196)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Control-high sodium (n = 193)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: DASH-high sodium
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: DASH-low sodium
Number of subjects: 588
Study: 32315461

Group type: EXPERIMENTAL
Intervention: Pharmacist-conducted medication review
Number of subjects: 10565

Group type: EXPERIMENTAL
Intervention: Drug Burden Index (DBI) assessment
Number of subjects: 10565

Group type: EXPERIMENTAL
Intervention: Risk of falling assessment
Number of subjects: 10565
Study: 35960166

Group type: COMPARATOR
Intervention: Real neurofeedback (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham neurofeedback (n=12)
Number of subjects: 24
Study: 34607238

Group type: EXPERIMENTAL
Intervention: Negative media item on lamotrigine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nocebo explanation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 32092717

Group type: EXPERIMENTAL
Intervention: Bisoprolol patch
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study: 35780813

Group type: EXPERIMENTAL
Intervention: COVID‐19 convalescent plasma (n=487)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Placebo (n=473)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Placebo (n=465)
Number of subjects: 974